Milestone is a biopharmaceutical company dedicated to developing and commercializing innovative cardiovascular solutions to improve the lives of people living with disruptive, episodic heart conditions.

Etripamil is a novel calcium channel blocker conceived, developed and manufactured by Milestone.

Etripamil is currently being studied as a potential treatment for PSVT in pediatric patients and symptomatic atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults.

For information regarding access to Milestone’s clinical trials, please visit clinicaltrials.gov.